Skip to main content

Table 2 General features of the studies included

From: Bleeding outcomes associated with rivaroxaban and dabigatran in patients treated for atrial fibrillation: a systematic review and meta-analysis

Studies Type of study Patients’ enrollment period No of patients in Rivaroxaban group (n) No of patients in Dabigatran group (n)
Gorst 2016 [8] Observational 2012–2014 360 1190
Larock 2014 [9] Observational - 35 34
Maura 2015 [10] Observational 2012 851 1687
Providencia 2014 [11] Observational 2012–2013 188 176
Sherid 2014 [12] Observational 2010–2013 147 227
Total no of patients (n)    1581 3314
  1. Study Gorst 2016 included a very large number of patients. However, the other studies consisted of less patients. Therefore, in order for the result of this analysis not to be influenced by the result of study Gorst 2016, only patients with diabetes mellitus were selected from that particular study